# Becton Dickinson & Co: overview

BDX · NYSE · CIK 10795 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/bdx.md) · [Financials](/companies/bdx/financials.md) · [Filings](/companies/bdx/filings.md) · [Insiders](/companies/bdx/insiders.md)

Latest reported revenue: [$4.98bn](/filings/0000010795-26-000035.md) for Q3 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0000010795-26-000035).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [5,437 d](/filings/0000010795-25-000099.md) | [5,168](/filings/0000010795-26-000005.md) | [4,480](/filings/0000010795-26-000026.md) | [4,726](/filings/0000010795-26-000035.md) | [8,301 d](/filings/0000010795-25-000099.md) | [5,252](/filings/0000010795-26-000005.md) | [4,714](/filings/0000010795-26-000026.md) | [4,983](/filings/0000010795-26-000035.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [11.4% d](/filings/0000010795-25-000099.md) | [8.8%](/filings/0000010795-26-000005.md) | [8.5%](/filings/0000010795-26-000026.md) | [15.6%](/filings/0000010795-26-000035.md) | [14.1% d](/filings/0000010795-25-000099.md) | [10.5%](/filings/0000010795-26-000005.md) | [2.0%](/filings/0000010795-26-000026.md) | [13.3%](/filings/0000010795-26-000035.md) |
| Net margin | % | [7.4% d](/filings/0000010795-25-000099.md) | [5.9%](/filings/0000010795-26-000005.md) | [6.9%](/filings/0000010795-26-000026.md) | [12.1%](/filings/0000010795-26-000035.md) | [5.9% d](/filings/0000010795-25-000099.md) | [7.3%](/filings/0000010795-26-000005.md) | [(6.6%)](/filings/0000010795-26-000026.md) | [7.6%](/filings/0000010795-26-000035.md) |
| Diluted EPS | $ per share | not reported | [1.04](/filings/0000010795-26-000005.md) | [1.07](/filings/0000010795-26-000026.md) | [2.00](/filings/0000010795-26-000035.md) | not reported | [1.34](/filings/0000010795-26-000005.md) | [(1.11)](/filings/0000010795-26-000026.md) | [1.37](/filings/0000010795-26-000035.md) |
| Free cash flow | $m | [882 d](/filings/0000010795-25-000099.md) | [588](/filings/0000010795-26-000005.md) | [(318) d](/filings/0000010795-26-000026.md) | [925 d](/filings/0000010795-26-000035.md) | [1,475 d](/filings/0000010795-25-000099.md) | [549](/filings/0000010795-26-000005.md) | [546 d](/filings/0000010795-26-000026.md) | [633 d](/filings/0000010795-26-000035.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-09-30) | FY2022 (2022-09-30) | FY2023 (2023-09-30) | FY2024 (2024-09-30) | FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [19.1](/filings/0000010795-23-000098.md) | [18.9](/filings/0000010795-24-000084.md) | [19.4](/filings/0000010795-25-000099.md) | [20.2](/filings/0000010795-25-000099.md) | [21.8](/filings/0000010795-25-000099.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [11.8%](/filings/0000010795-23-000098.md) | [12.1%](/filings/0000010795-24-000084.md) | [10.9%](/filings/0000010795-25-000099.md) | [11.9%](/filings/0000010795-25-000099.md) | [11.8%](/filings/0000010795-25-000099.md) |
| Net margin | % | [10.9%](/filings/0000010795-23-000098.md) | [9.4%](/filings/0000010795-24-000084.md) | [7.7%](/filings/0000010795-25-000099.md) | [8.4%](/filings/0000010795-25-000099.md) | [7.7%](/filings/0000010795-25-000099.md) |
| Diluted EPS | $ per share | [6.85](/filings/0000010795-23-000098.md) | [5.88](/filings/0000010795-24-000084.md) | [4.94](/filings/0000010795-25-000099.md) | [5.86](/filings/0000010795-25-000099.md) | [5.82](/filings/0000010795-25-000099.md) |
| Free cash flow | $bn | [3.5](/filings/0000010795-21-000091.md) | [1.5](/filings/0000010795-24-000084.md) | [2.1](/filings/0000010795-25-000099.md) | [3.1](/filings/0000010795-25-000099.md) | [2.7](/filings/0000010795-25-000099.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bdx/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-26 | [Feld Michael](/insiders/2034349.md) | EVP, Chief Revenue Officer, Officer | Sale (S) | 76 | $198.13 | $15.1k | [Form 4](/filings/0001628280-26-067525.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $3.72bn | 24,592,166 |  | Reduced −1,561,245 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.72bn | 17,987,834 |  | Reduced −502,776 |
| [MASSACHUSETTS FINANCIAL SERVICES CO /MA/](/funds/912938.md) | 2026-06-30 | $2.48bn | 8,650,967 |  | Reduced −450,487 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $2.27bn | 15,000,064 |  | Added +1,177,256 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $2.27bn | 14,974,136 |  | Reduced −343,106 |
| [First Eagle Investment Management, LLC](/funds/1325447.md) | 2026-06-30 | $2.09bn | 13,815,335 |  | Added +1,887,224 |
| [First Eagle Investment Management, LLC](/funds/1325447.md) | 2026-06-30 | $2.09bn | 13,815,335 |  | Added +1,887,224 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $1.35bn | 8,898,488 |  | Reduced −1,275,839 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.23bn | 8,141,586 |  | Added +1,034,323 |
| [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $1.06bn | 7,011,592 |  | Added +1,648,627 |

## Recent filings

[All 2,026 filings](/companies/bdx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 16:36 ET | [10-Q](/filings/0000010795-26-000035.md) | Quarterly report, period 2026-06-30 | 0000010795-26-000035 |
| 2026-08-06 | 06:31 ET | [8-K](/filings/0001628280-26-053790.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-053790 |
| 2026-07-22 | 06:58 ET | [8-K](/filings/0001628280-26-049103.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-049103 |
| 2026-05-29 | 08:39 ET | [8-K](/filings/0001628280-26-039005.md) | 7.01 Regulation FD disclosure | 0001628280-26-039005 |
| 2026-05-20 | 17:05 ET | [8-K](/filings/0001140361-26-022270.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001140361-26-022270 |
| 2026-05-12 | 16:30 ET | [8-K](/filings/0001140361-26-020828.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-020828 |
| 2026-05-07 | 16:34 ET | [10-Q](/filings/0000010795-26-000026.md) | Quarterly report, period 2026-03-31 | 0000010795-26-000026 |
| 2026-05-07 | 06:33 ET | [8-K/A](/filings/0001628280-26-031642.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-031642 |
| 2026-05-07 | 06:30 ET | [8-K](/filings/0001628280-26-031638.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-031638 |
| 2026-04-29 | 16:16 ET | [8-K](/filings/0000010795-26-000012.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0000010795-26-000012 |

## Latest annual report

[Form 10-K for the fiscal year ended Sep 30, 2025](/filings/0000010795-25-000099.md), filed Nov 25, 2025.

## Forecast league

Q4 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/5bed8386-28ed-45c1-96f6-bfd440cb0d93)

## About the filer

- CIK: 10795
- Tickers: BDX
- Exchange: NYSE
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: NJ
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 14:28 ET. No prices; not investment advice.